

NEUROPEPTIDI KAO POTENCIJALNI SUPSTRATI I INHIBITORI LJUDSKE DPP3

Zrinka Karačić, 23. rujna 2022.

Minisimpozij DPP3

NAŠ NOVI RAD PRIHVAĆEN!



International Journal of Biological
Macromolecules

Volume 220, 1 November 2022, Pages 1390-1401




Neuropeptides, substrates and inhibitors of
human dipeptidyl peptidase III, experimental
and computational study — A new substrate
identified

Zrinka Karačić^{a, 1}✉, Filip Šupljika^{b, 1}✉, Antonija Tomić^a✉, Lidija Brkljačić^a✉, Ana Tomašić Paić^a✉, Mirsada Čehić^a✉, Sanja Tomić^a✉

METODE

Ana Tomašić Paić
Lidija Brkljačić






Cijepanje
HPLC-MS

Inhibicija
FLUO


Mirsada
Čehić

Kinetika
ITC



Vežanje
ITC


d) Leu-enkephalin



Filip
Šupljika

CIJEPANJE

- 1 mM peptidi inkubirani uz veliku koncentraciju enzima (0,18 μM) 2h (ili manje) i 24h
- HPLC-MS korišten za određivanje količine preostalog peptida, kao i detekciju produkata odgradnje
- U 200 μL reakcijske smjese dodano 100 μL acetonitrila za zaustavljanje enzimske reakcije, pa pohranjeno na -20°C
- Primjer: angiotenzin II



INHIBICIJA

- Inhibicija peptidima kao kompetitivnim inhibitorima – mjerenje brzine reakcije cijepanja supstrata Arg₂-2NA uz 3 različite koncentracije inhibitora
- Određivanje K_i nelinearnom regresijom
- Primjer: inhibicija nM tinorfinom






Table 1

Interaction of human DPP III with neuropeptides: peptide degradation was studied using HPLC-MS, and inhibition constants K_i were measured for inhibition of human DPP III in reaction with a fluorescent substrate analogue. The peptides are sorted according to increasing K_i .

Peptide	Sequence	Cleaved ^a	$K_i/\mu\text{M}^b$
I-tyrnorphin	IVYPW	Y	0.00045 ± 0.00005
S-tyrnorphin	SVYPW	Y	0.0077 ± 0.0007
Tynorphin	VVYPW	Y	0.0112 ± 0.0008
Valorphin	VVYPWTQ	Y	0.0365 ± 0.0029
β -Casomorphin	YPFVEPI	Y	1.0 ± 0.1
Angiotensin II	DRVYIHPF	Y	4.4 ± 0.5
Leu-valorphin-Arg	LVVYPWTQR	Y	5.2 ± 0.5
Hemorphin-4	YPWT	Y	6.5 ± 0.7
Endomorphin-2	YFFF	Y	10.4 ± 1.0
Leu-enkephalin	YGGFL	Y	10.4 ± 1.4
Arg-vasopressin	C*YFQNC*PRG	N	n.d. ^c
Hemopressin	PVNFKFLSH	N	n.d.
β -Neoendorphin	YGGFLRKYP	N	n.d.

* Denoting a disulfide bridge.


^a Cleavage (Y yes or N no) determined by HPLC-MS as reduction of peptide amount after incubation of 1 mM peptide with 0.18 μM enzyme after 24 h at 25 °C in ammonium bicarbonate buffer pH = 7.4.

^b Inhibition constant for inhibition of enzyme-catalyzed cleavage of artificial substrate Arg₂-2NA at 25 °C in 20 mM TrisHCl buffer pH = 7.5.

^c No inhibition trend detected with peptide in the range of 1–50 μM .

VEZANJE

- Mikrokalorimetrijska mjerenja (ITC = izotermalna titracijska kalorimetrija) interakcije peptida i inaktivnog mutanta E451A
- Određeni parametri: konstanta vezanja, reakcijska Gibbsova energija, entalpija i entropija
- Pretpostavka N=1
- Endotermni proces, entropijski vođen



ITC VEZANJE

Table 2

Thermodynamic parameters of peptide binding to human DPP III at 25 °C and pH = 7.5 in 20 mM TrisHCl buffer.

Peptide	$K_d/\mu\text{M}$	$\Delta_r H/$ kcal mol ⁻¹	$\Delta_r G /$ kcal mol ⁻¹	$-T^*\Delta_r S /$ kcal mol ⁻¹
I-tynorphin	0.0973 ± 0.0091	8.01 ± 0.24	-9.58 ± 0.05	-17.6 ± 0.2
S-tynorphin	0.298 ± 0.061	5.69 ± 0.24	-8.91 ± 0.12	-14.7 ± 0.4
tynorphin	0.386 ± 0.127	6.19 ± 0.29	-8.77 ± 0.19	-15.0 ± 0.1
valorphin	1.78 ± 0.21	4.64 ± 0.19	-7.86 ± 0.07	-12.5 ± 0.1
Angiotensin II	2.22 ± 0.24	6.17 ± 0.72	-7.72 ± 0.07	-13.9 ± 0.6
Leu-valorphin- Arg	2.50 ± 1.92	4.61 ± 2.15	-7.77 ± 0.45	-12.4 ± 1.8
Hemorphin-4	39.4 ± 14.6	8.70 ± 1.82	-6.05 ± 0.24	-14.7 ± 1.6
Endomorphin-2	40.1 ± 4.8			
Leu-enkephalin	118 ± 39			
β-Casomorphin	130 ± 87			
Arg-vasopressin	n. d.			
Hemopressin	n. d.			
β-Neoendorphin	n. d.			

n.d. – binding not detected.

KINETIKA

- Kalorimetrijski - ITC
- SIM – single injection – potpuna konverzija supstrata u produkt
- Primjer: SIM Leu-enkefalin i tinorfin

Spori supstrati:

- l/S/-tinorfin
- valorfin
- β -kazomorfin





Table 3

Kinetic parameters of peptide degradation as measured by ITC using SIM at 25 °C in 50 mM Tris-HCl buffer with 100 mM NaCl and pH = 8.0.

Peptide	$\Delta_r H / \text{kcal mol}^{-1}$	$K_M / \mu\text{M}$	$k_{\text{cat}} / \text{s}^{-1}$	$(k_{\text{cat}} / K_M) / \text{s}^{-1} \text{ M}^{-1}$
Leu-valorphin-Arg	-1.53 ± 0.07	33.9 ± 6.4	0.35 ± 0.09	$1.03 \dots 10^4$
Leu-enkephalin	-1.57 ± 0.02	34.7 ± 5.7	1.08 ± 0.12	$3.11 \dots 10^4$
Hemorphin-4	-1.79 ± 0.17	55.1 ± 13.1	6.11 ± 0.96	$1.11 \dots 10^5$

KINETIKA

- MIM – multiple injection – djelomična pretvorba do 5% supstrata u produkt tijekom svake injekcije supstrata u otopinu enzima
- Primjer: MIM Leu-enkefalin




Table S2. Kinetic parameters of peptide degradation as measured by ITC using MIM at 25 °C in 50 mM TrisHCl buffer with 100 mM NaCl and pH = 8.0

peptide	$K_M / \mu\text{M}$	$k_{\text{cat}} / \text{s}^{-1}$	$(k_{\text{cat}}/K_M) / \text{s}^{-1} \text{M}^{-1}$
Leu-valorphin-Arg	27.3	0.54	$1.98 \cdot 10^4$
Leu-enkephalin	33.7	2.38	$7.06 \cdot 10^4$
Hemorphin-4	75.6	5.21	$6.89 \cdot 10^4$

ZAKLJUČCI

- Uspješno uvedene nove metode:
 - Mikrokolorimetrija za praćenje kinetike peptidazne enzimske reakcije – SIM i MIM
 - HPLC-MS za ispitivanje peptida kao supstrata
- Postojeće metode nadopunjuju se s novima
- Potvrđen hemorfin-4 kao do sada nepoznati supstrat hDPP III

ŠTO DALJE?

Neurochem Res (2016) 41:2666–2674
DOI 10.1007/s11064-016-1979-9

ORIGINAL PAPER

A Group of Weakly Bound to Neurons Extracellular Metallopeptidases (NEMPs)

Ekaterina S. Kropotova^{1,2} · Mark I. Mosevitsky^{1,2}

Biochemical and Biophysical Research Communications 616 (2022) 110–114



ELSEVIER

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



- Endogeni inhibitori enkefalinaza:
- **Opiorfin** i sialorphin: **QRFSR** i QHNPR
 - inhibitor NEP i APN

Dipeptidylamino-tripeptidylcarboxypeptidase NEMP3 and DPP3 (DPP III) are the same protein

Ekaterina S. Kropotova^{a, b}, Ekaterina N. Pavlova^b, Stanislav N. Naryzhny^a,
Mark I. Mosevitsky^{a, b, *}

